Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHINE I single-dose HPV vaccine immunobridging study
PACTR202407768096289Phase 3Unknown
- Sponsor
- PATH
- Start
- Jan 2025
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection and cancer prevention, sponsored by PATH. Status: unknown.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectioncancer prevention
Beyond the preview
Go deeper on PACTR202407768096289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202407768096289.